2 terminated. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
Follow olaratumab: new trials by email Literature Review of olaratumab trials Research Report on olaratumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients Olaratumab, Dexrazoxane, Doxorubicin - Advanced Soft Tissue Sarcoma | Phase 2 | Terminated | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2 | 2018-11-12 | 2020-07-15 |
| A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors Olaratumab - Gastrointestinal Stromal Tumor (GIST) | Phase 2 | Terminated | Eli Lilly and Company | 21 | 2011-08-01 | 2017-03-09 |
Gastrointestinal Stromal Tumors (1) · Sarcoma (1)
Eli Lilly and Company (1) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1)
Germany (2) · Belgium (1) · Netherlands (1) · Poland (1) · Spain (1) · United States (1)
Salah-Eddin Al-Batran, Prof. Dr. (1)